Insight

Leila Tchelebi: Officially in print. Our QA Analysis of Alliance A021501

Photo from Leila Tchelebi/X

Aug 17, 2024, 07:54

Leila Tchelebi: Officially in print. Our QA Analysis of Alliance A021501

Leila Tchelebi, Associate Professor of Radiation Medicine at Zucker School of Medicine, shared a post on X, about a recent paper published in Science Direct.

“Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas”

Authors: Leila Tchelebi et al.

“Officially in print! Our QA Analysis of Alliance A021501, the 1st RCT of neoadjuvant SBRT for Pancreatic Cancer.”

Source: Leila Tchelebi/X

Adenocarcinoma Alliance A021501 Alliance for Clinical Trials in Oncology ASTRO cancer Joseph Michael Herman Leila Tchelebi Michael Chuong OncoDaily Oncology Pancreatic Cancer radiation therapy SBRT Science Direct Zucker School of Medicine

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage